Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $190.7552W HIGH $274.94
Volume
154.67 K
Value Traded
1.04 B
Short % Float
1.1%
+3.65%Week
+8.57%1 Month
+9.81%3 Month
+31.01%6 Month
+83.54%5 Year
+482.97%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
483.78 B
EPS (TTM)
3.57
P/E Ratio
76.29
Ent. Value
474.74 B
Total Shares
1.77 B
Float Shares
1.77 B
Insiders
0.10%
Institutions
78.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ABBV Catalyst Timeline
Dated clinical, regulatory and corporate events for AbbVie Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AbbVie Inc.
2768Total events
27Upcoming
1169Tier-1 (high impact)
2013 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Breakthrough Therapy Designationtelisotuzumab adizutecanDesignation
FDA grants Breakthrough Therapy Designation to Temab-A plus bevacizumab in refractory metastatic CRC
refractory, metastatic colorectal cancer (CRC)source ↗
▲Topline ReadoutEpcoritamabApprovedClinical Data
Positive topline results from Phase 3 EPCORE DLBCL-2 of epcoritamab plus R-CHOP in newly diagnosed DLBCL
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Secondary Endpoint DataEpcoritamabApprovedClinical Data
Key secondary endpoint of PFS in total participants (IPI 2-5) met with 51% risk reduction
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Safety Data UpdateEpcoritamabApprovedClinical Data
Epcoritamab plus R-CHOP safety profile generally well tolerated in EPCORE DLBCL-2
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲DSMB ReviewEpcoritamabApprovedTrial
IDMC recommended unblinding EPCORE DLBCL-2 based on significant benefit
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Primary Endpoint MetEpcoritamabApprovedClinical Data
EPCORE DLBCL-2 met primary endpoint of PFS in IPI 3-5 patients
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Interim AnalysisEpcoritamabApprovedTrial
First planned efficacy interim analysis of EPCORE DLBCL-2
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
◆Oral PresentationUpadacitinibApprovedPresentation
Oral presentation of pooled patient-reported outcomes with upadacitinib in nonsegmental vitiligo through Week 48 from two Phase 3 trials
non-segmental vitiligosource ↗
◆Late-BreakerUpadacitinibApprovedPresentation
Late-breaking presentation of upadacitinib efficacy and safety in adolescents and adults with non-segmental vitiligo at Week 76 and in combination with NB-UVB therapy
non-segmental vitiligosource ↗
◆Oral PresentationUpadacitinibApprovedPresentation
Oral presentation on impact of upadacitinib on clinician- and patient-reported outcomes assessing visible hair loss at key sites in severe alopecia areata
severe alopecia areatasource ↗
●Oral PresentationUpadacitinibApprovedPresentation
Late-breaking oral presentation of long-term Viti-Up data at 2026 EADV Congress
non-segmental vitiligosource ↗
●Safety Data UpdateUpadacitinibApprovedClinical Data
Safety results through week 76 consistent with known upadacitinib profile
non-segmental vitiligosource ↗
▲Long Term DataUpadacitinibApprovedClinical Data
Continued F-VASI 75 and T-VASI 50 repigmentation through week 76 in OLE
non-segmental vitiligosource ↗
▲Additional DataUpadacitinibApprovedClinical Data
Week 28 results of RINVOQ plus NB-UVB phototherapy substudy
non-segmental vitiligosource ↗
▲Late-BreakerUpadacitinibApprovedPresentation
Late-breaking results from Phase 3 Viti-Up-1 and Viti-Up-2 presented at 2026 EADV Congress
non-segmental vitiligosource ↗
▲Primary Endpoint MetzumilokibartClinical Data
Zumilokibart met primary endpoint (EASI-75 at Week 16) in Phase 2 APEX Part B
moderate to severe atopic dermatitissource ↗
◆Late-BreakerzumilokibartPresentation
Late-breaking presentation of primary 16-week results from Phase 2 APEX Part B dose-regimen-finding study of zumilokibart in moderate to severe AD
moderate to severe atopic dermatitissource ↗
▲Oral PresentationABBV-295Presentation
Detailed Phase 1 MAD results for ABBV-295 presented at EASD 2026
obesitysource ↗
◆Poster PresentationzumilokibartPresentation
Digital e-poster on efficacy of zumilokibart in patients with atopic dermatitis and evidence of type 2 inflammatory comorbidities from Phase 2 APEX Part A study
atopic dermatitissource ↗
◆Poster PresentationLutikizumabPresentation
Digital e-poster on patient-reported quality of life and disease burden in biologic-naive adults with moderate-to-severe HS treated with lutikizumab from Phase 2 study
hidradenitis suppurativasource ↗
◆Poster PresentationUpadacitinibApprovedPresentation
Digital e-poster on efficacy of upadacitinib in patients with itch-dominant atopic dermatitis from Phase 3 Measure Up 1 and 2 trials
atopic dermatitissource ↗
◆Late-BreakerLutikizumabPresentation
Late-breaking presentation showing lutikizumab targets neutrophilic inflammation and fibroblast activation in HS
hidradenitis suppurativasource ↗
◆Poster PresentationRisankizumabApprovedPresentation
Digital e-poster on efficacy of risankizumab in prevention of radiographic progression in PsA patients at low and high risk of joint erosive disease: 5-year data from Phase 3 KEEPsAKE 1 trial
psoriatic arthritissource ↗
▲Secondary Endpoint DatazumilokibartClinical Data
Mid- and high-dose regimens showed significant improvements in EASI 90/100 and I-NRS4 vs placebo
moderate to severe atopic dermatitissource ↗
●Safety Data UpdatezumilokibartClinical Data
Safety data reported for zumilokibart through Week 16
moderate to severe atopic dermatitissource ↗
▲Partnership / LicenseCorporate
AbbVie enters AI collaboration with Valkai across clinical development
▲FDA ApprovalJUVMOApprovedFDA Decision
U.S. FDA approves JUVMO (tavapadon) for adults with Parkinson's disease
Parkinson's diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
Construction phase completed for AbbVie Foundation Cancer Pavilion
▲EU ApprovalUpadacitinibApprovedEx-US Regulatory
European Commission approves RINVOQ for active polyarticular juvenile idiopathic arthritis in patients 2 years and older
active polyarticular juvenile idiopathic arthritis (pJIA)source ↗
▲FDA ApprovalUpadacitinibApprovedFDA Decision
New oral solution of RINVOQ approved for use in patients with pJIA
active polyarticular juvenile idiopathic arthritis (pJIA)source ↗
▲Partnership / LicenseCorporate
AbbVie and Iambic announce multi-year collaboration for AI-driven small molecule discovery
▲RWE DataCariprazineApprovedClinical Data
ProACt interim real-world data of adjunctive VRAYLAR in MDD presented at Psych Congress 2026
major depressive disorder (MDD)source ↗
●Additional DataCariprazineApprovedClinical Data
Indirect comparative analysis of cariprazine and lumateperone as adjunctive MDD treatment presented
major depressive disorder (MDD)source ↗
▲Long Term DataCariprazineApprovedClinical Data
Final long-term pediatric safety and tolerability results for VRAYLAR presented
bipolar I disorder, schizophrenia or autism spectrum disorder (pediatric)source ↗
●Additional DataCariprazineApprovedClinical Data
MDD patient survey on augmenting vs switching antidepressants presented at Psych Congress 2026
major depressive disorder (MDD)source ↗
●RWE DataClinical Data
MDD patient survey on augmenting vs switching antidepressants presented
major depressive disorder (MDD)source ↗
▲Interim Efficacy DataCariprazineApprovedClinical Data
ProACt interim findings presented at Psych Congress 2026 showing improvements in depressive symptoms, functioning, motivation, energy and anhedonia
Major depressive disorder (MDD)source ↗
●Poster PresentationPresentation
E-posters on skin quality improvements with skincare regimen and with dermabrasion plus skincare regimen presented at Science of Skin Summit
skin quality in individuals taking medical weight loss medicationssource ↗
▲Full ResultsClinical Data
Results from six-week DiamondGlow plus skincare study in individuals taking medical weight loss medications
skin quality improvements in individuals taking medical weight loss medicationssource ↗
▲Topline ReadoutAtogepantApprovedClinical Data
AbbVie announced positive topline results from Phase 3 LUNA study of atogepant in menstrual migraine
menstrual migrainesource ↗
▲Primary Endpoint MetAtogepantApprovedClinical Data
Atogepant met primary endpoint in Phase 3 LUNA study, demonstrating 0.80 fewer migraine days versus placebo (p<0.0001)
menstrual migrainesource ↗
▲Secondary Endpoint DataAtogepantApprovedClinical Data
Atogepant met all eight ranked secondary endpoints in Phase 3 LUNA study (p<0.0001)
menstrual migrainesource ↗
●Safety Data UpdateAtogepantApprovedClinical Data
Safety results from Phase 3 LUNA study consistent with known safety profile of atogepant, no new safety signals
menstrual migrainesource ↗
▲Topline ReadoutEtentamigClinical Data
Positive topline results from Phase 3 CERVINO trial
relapsed/refractory multiple myelomasource ↗
▲Interim AnalysisEtentamigTrial
First planned efficacy interim analysis of CERVINO
relapsed/refractory multiple myelomasource ↗
◆Poster PresentationSurzetoclaxPresentation
Poster on surzetoclax BCL-2 inhibitor in multiple myeloma with t(11;14) or high BCL-2 expression at IMS 2026
multiple myeloma with t(11;14) translocation or high BCL-2 expressionsource ↗
●EU MAA SubmissionSKYRIZIApprovedEx-US Regulatory
Submitted application to EMA for SKYRIZI subcutaneous induction in Crohn's disease
moderately to severely active Crohn's diseasesource ↗
▲Topline ReadoutSKYRIZIApprovedClinical Data
Positive data from Phase 3 AFFIRM study shared
moderately to severely active Crohn's diseasesource ↗
●sBLA SubmissionOnabotulinumtoxinAApprovedRegulatory Filing
sBLA submitted for BOTOX Cosmetic for masseter muscle prominence
masseter muscle prominencesource ↗
▲FDA Filing AcceptedOnabotulinumtoxinAApprovedRegulatory Filing
FDA accepted sBLA for review for BOTOX Cosmetic for masseter muscle prominence
masseter muscle prominencesource ↗
Past FDA Catalysts and PDUFA Decisions
How ABBV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-02 | RINVOQ (upadacitinib) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A81 / 100
Pipeline Score
$26.1B
Pipeline Value
$273.0B
Commercial Value
Overvalued
Valuation Signal
123
Drugs Scored
0.1x
rNPV / MCap
Top 2%
Large Pharma(rank 14 of 658)
Percentile Rank
AbbVie Inc. earns an A-grade pipeline score (81/100), with $26.1B risk-adjusted pipeline value, led by ABBV-1480 in Non-Small Cell Lung Cancer (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $64.4B x 4.2 = $273.0B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| SKYRIZI | $19.7B | $14.8B | +32.8% |
| RINVOQ | $9.2B | $7.2B | +27.9% |
| Botox Therapeutic | $4.0B | $3.5B | +14.5% |
| Vraylar | $3.9B | $3.5B | +13.5% |
| HUMIRA | $3.7B | $6.2B | -40.7% |
| VENCLEXTA | $3.0B | $2.7B | +10.8% |
| Botox Cosmetic | $2.8B | $2.6B | +5.5% |
| Imbruvica | $2.5B | $3.2B | -22.2% |
| Creon | $1.5B | $1.5B | -1.8% |
| Ubrelvy | $1.4B | $1.2B | +23.8% |
| MAVYRET | $1.3B | $1.3B | +0.6% |
| Qulipta | $1.2B | $837M | +46% |
Top 12 of 17 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV-1480 Small moleculeNCT07756645 | Non-Small Cell Lung Cancer | Phase 3 | NOT YET_RECRUITING | 940 | Dec 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABBV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| epcoritamab BreakthroughPriorityAccelerated | newly diagnosed diffuse large B-cell lymphoma | Phase 3 | 2026-10-05 | 51% reduction in the risk of disease progression or death (HR 0.49 [95% CI 0.36, 0.67]; p-value < 0.0001)Read More | AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell LymphomaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Donoghoe NicholasOfficer (EVP, CHIEF BUS/STRAT OFFICER) | Option | 32,710 107,140 held | $79.02 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABBV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.7 % (-22.7 %) | 16.31 M | 75.00 K | 64% ( 29.27 K) |
ABBV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-01-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABBV ranks across every disease it competes in
Competitive Position is a premium feature
See how ABBV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABBV News
ABBV▲ +0.6%today
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
AbbVie announced that its investigational drug, telisotuzumab adizutecan (Temab-A), has received two Breakthrough Therapy Designations from the FDA for colorectal cancer and non-small cell lung cancer. These designations underscore the drug's potential as a treatment for patients with advanced solid tumors. Temab-A is being studied both as a monotherapy and in combination with other therapies.
Read more →ABBV▲ +0.6%today
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, which evaluated the bispecific antibody epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The trial demonstrated a 51% reduction in the risk of disease progression or death, indicating a significant improvement in progression-free survival. The companies plan to engage global regulatory authorities based on these results.
Read more →ABBV▲ +0.6%today
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, demonstrating that the bispecific antibody epcoritamab in combination with R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL patients. The study showed a 51% reduction in the risk of disease progression or death. The companies plan to engage global regulatory authorities based on these findings.
Read more →ABBVAbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
AbbVie presented long-term data on RINVOQ (upadacitinib) at the 2026 EADV Congress, demonstrating sustained facial and total body repigmentation in non-segmental vitiligo patients through week 76. The Phase 3 Viti-Up studies indicated improved outcomes when RINVOQ was combined with NB-UVB phototherapy. Safety results remained consistent with previous findings, with no new safety concerns reported.
Read more →ABBVAbbVie to Host Third-Quarter 2026 Earnings Conference Call
AbbVie will announce its third-quarter 2026 financial results on October 30, 2026, before market opening. A live webcast of the earnings conference call will take place at 8 a.m. Central time, accessible via AbbVie's Investor Relations website. An archived version will be available later that day.
Read more →ABBVAbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, at the EASD 2026 Annual Meeting. The study showed favorable pharmacokinetics, including a half-life of approximately 11-12 days, and demonstrated meaningful weight loss across multiple dosing regimens. The results support advancing ABBV-295 into Phase 2 development for chronic weight management.
Read more →ABBVAbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
AbbVie announced positive results from the Phase 2 APEX Part B study of zumilokibart for moderate to severe atopic dermatitis. All dose regimens met the primary endpoint, with significant improvements in skin lesions and itch. The mid-dose regimen has been selected for Phase 3 development, supporting its potential as a long-term treatment option.
Read more →ABBVAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie showcased its leadership in dermatology research at the 2026 EADV Congress, presenting 60 abstracts across various immune-mediated skin diseases. Key findings included new data on risankizumab and upadacitinib, which support their efficacy and safety. Investigational therapies lutikizumab and zumilokibart were also highlighted, indicating AbbVie's commitment to advancing treatment options for patients.
Read more →ABBVAbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
AbbVie has partnered with Valkai to enhance its artificial intelligence capabilities in clinical development. This collaboration aims to streamline research processes, generate insights more rapidly, and ultimately improve patient outcomes. The initiative reflects AbbVie's commitment to integrating AI throughout its drug development journey, leveraging advanced technology alongside human expertise.
Read more →ABBVGinkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Ginkgo Datapoints and Apheris have announced the inclusion of AbbVie, argenx, Lundbeck, and Takeda as founding members of the Antibody Developability Consortium. This collaboration aims to enhance the development processes for antibodies, leveraging the expertise of these leading biopharma companies. The consortium is expected to drive innovation in the field.
Read more →ABBVU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
The U.S. FDA has approved AbbVie's JUVMO™ (tavapadon) as the first selective D1/D5 receptor agonist for adults with Parkinson's disease. This novel treatment offers a new approach to managing motor symptoms and has shown significant efficacy in clinical trials, reducing the need for increased doses of oral levodopa. JUVMO is expected to be available to patients in October 2026.
Read more →ABBVUChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality
The University of Chicago Medicine has completed the construction of the AbbVie Foundation Cancer Pavilion, a 575,000-square-foot facility dedicated to cancer care. Set to open in April 2027, this project aims to enhance access to advanced cancer treatments and improve health outcomes in underserved communities. The pavilion will serve approximately 200,000 outpatient visits and 5,000 inpatient admissions annually.
Read more →ABBVEPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
AbbVie has received Health Canada approval for EPKINLY (epcoritamab) to treat adults with relapsed or refractory follicular lymphoma. This approval is based on the Phase 3 EPCORE FL-1 study, which demonstrated a 79% reduction in the risk of disease progression when EPKINLY is combined with lenalidomide and rituximab. This new treatment option is crucial for patients facing lymphoma recurrence.
Read more →ABBVAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie has received European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiopathic arthritis (pJIA) in children aged two and older who have not responded adequately to DMARDs. The approval is based on the SELECT-YOUTH Phase 1 study, demonstrating significant efficacy and safety. RINVOQ is now approved for 11 indications in the EU, expanding treatment options for pediatric patients.
Read more →ABBVAbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
AbbVie and Iambic have announced a multi-year collaboration to enhance small molecule drug discovery using Iambic's AI-driven platform. The partnership aims to leverage AI capabilities to improve efficiency in identifying promising drug candidates across immunology, neuroscience, and oncology. This collaboration is expected to lead to the development of first-in-class and best-in-class therapies, ultimately benefiting patients.
Read more →ABBVAbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
AbbVie presented new real-world data on VRAYLAR (cariprazine) at Psych Congress 2026, demonstrating its effectiveness in treating major depressive disorder (MDD) and bipolar I depression. The studies showed significant improvements in depressive symptoms, functioning, and quality of life among patients. These findings support the efficacy of VRAYLAR observed in clinical trials, emphasizing its value in everyday clinical practice.
Read more →ABBVAbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
AbbVie will present results from the Phase 3 CERVINO study at the 2026 IMS Meeting, demonstrating that etentamig achieved significant improvements in objective response rate and progression-free survival for patients with relapsed/refractory multiple myeloma. The company will also showcase its extensive myeloma research portfolio, including innovative therapies like ABBV-2001 and surzetoclax, emphasizing its commitment to addressing the complexities of the disease.
Read more →ABBVAllergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
Allergan Aesthetics presented results from two clinical studies at the 2026 Science of Skin Summit, showcasing improvements in skin quality for individuals on medical weight loss medications. The studies demonstrated significant enhancements in skin measures and high participant satisfaction. Findings suggest potential benefits of targeted skincare and dermabrasion treatments in this demographic.
Read more →ABBVAbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
AbbVie and BioLabs University of Toronto have opened applications for the AbbVie Biotech Innovators Award, aimed at supporting early-stage biotechnology companies in Ontario. The award will provide selected companies with laboratory space, resources, and mentorship to accelerate their development of innovative healthcare solutions. Applications are open until November 10, 2026.
Read more →ABBVAbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
AbbVie has partnered with the PGA TOUR as its Official Pharmaceutical Sponsor, launching the Birdies for Brain Health campaign. This initiative aims to raise awareness and support for individuals living with neurological conditions. The campaign will debut at the 2026 Presidents Cup, with donations benefiting six advocacy organizations. It will expand to PGA TOUR Signature Events in 2027.
Read more →About AbbVie Inc.
Headquarters1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next ABBV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime